| PharmaSUG CN |
2026 |
An Integrated, AI-Augmented R Shiny Platform for Oncology Clinical Trial Decision Intelligence: From CDISC Data to Go/No-Go in One Unified Hub |
Zhiping Yan |
source |
28 |
| PharmaSUG CN |
2026 |
Implementing a Single-Agent Bayesian Logistic Regression Model in SAS for Dose Escalation in Phase I Oncology Trials |
Zhanwen Peng |
source |
11 |
| PHUSE US |
2026 |
AI-Augmented Bayesian Methods for Late-Onset Toxicity in Early-Phase Trials |
Rachana Lele,
Arfan Afzal |
source
presentation source |
8 |
| PHUSE APAC |
2026 |
Beyond Toxicity : Accelerating Dose -Finding with Pharmacokinetic -Driven Bayesian Design PKBOIN-12 |
Anetta Mary Xavier |
source
presentation source |
13 |
| PharmaSUG |
2025 |
Cytokine Release Syndrome (CRS) - Data Collection, Clinical Database Integration and Analyses in a Dose Escalation Cell Therapy Trial |
Cyrille Correia,
Venky Chakravarthy |
source |
13 |
| PHUSE US |
2025 |
Standardised and Automated Template for Dose Escalation Decision-Making |
Jasmina Uzunovic,
Aditi Qamra |
source
presentation source |
6 |
| PharmaSUG |
2024 |
A Programmer-s Insight into an Alternative to TQT Study Data Submission |
Hiba Najeeb,
Raghavender Ranga |
source |
7 |
| PHUSE US |
2023 |
Common Sample Size Calculations for Phase I/IIa Clinical Trials [presentation] |
Aayush Bhoraskar |
source
video |
13 |
| PharmaSUG |
2022 |
Standardizing Procedures for Generating Dose Proportionality Figures to Improve Programming Efficiency |
Jianli Ping,
Krishna Sivakumar |
source |
11 |
| PHUSE US |
2020 |
Graphical Presentation of Patient Profiles in Dose Escalation Trials Using SAS GTL [poster] |
Chiu Tsang,
Rita Tsang |
source |
1 |
| PHUSE EU |
2019 |
Dose-finding Schemes in Clinical Trials |
Michael Brockmann |
source
presentation source |
15 |
| PHUSE US |
2019 |
Graphical Examination of PK Parameters Versus Dose-in-Dose Escalation Trials using SAS GTL |
Chiu Tsang,
Hima Bhatia |
source
poster source |
9 |
| PHUSE US |
2018 |
Challenges and Opportunities for Real-time Clinical Data Review [poster] |
Renu Shukla |
source |
1 |
| PharmaSUG |
2017 |
Visualizing Enrollment Over Time |
Laura Gruetzner |
source |
11 |
| PharmaSUG |
2016 |
A Dose Escalation Method for Dual-Agent in Phase 1 Cancer Clinical Trial using the SAS MCMC Procedure |
Gwénaël Le Teuff,
Mohamed Amine Bayar |
source |
14 |
| PHUSE EU |
2015 |
Establish the Maximum Tolerated Dose in Phase 1 Trials Using the 3+3 Method |
Anup Pillai |
source
presentation source |
12 |
| PharmaSUG |
2014 |
Automating the Number of Treatment Columns for a Dose Escalation Study |
Catherine DeVerter,
Sonali Garg |
source |
5 |
| PharmaSUG |
2010 |
The CDISC/FDA Integrated Data Pilot: A Final Summary of Findings, Reviewer Feedback, and Recommendations Implementing CDISC Standards Within and Across Studies |
Chris Decker |
|
20 |
| PHUSE EU |
2009 |
Moving from Full Development to Translational Medicine |
Nassim Sleiman |
source |
5 |
| PHUSE EU |
2009 |
The CDISC/FDA Integrated Data Pilot: A Case Study in Implementing CDISC Standards to support an Integrated Review |
Chris Decker |
source
presentation source |
15 |
| PHUSE EU |
2007 |
WEB-TRIAGE: Application for patient registration in ph I studies |
Angelo Tinazzi,
Lucio Ferraresi |
source |
10 |
| MWSUG |
2005 |
Using SAS To Assess Dose Proportionality In Dose Escalation Studies |
Keith Dunnigan |
|
12 |
| PharmaSUG |
2001 |
Unit-of-Analysis Programming |
Vanessa C. Hayden,
Fidelity Investments |
|
6 |
HOME
QUICK SEARCH
AUTHORS
KEYWORDS
HELP
BUGS